Electrocardiographic and clinical predictors for permanent pacemaker requirement after transcatheter aortic valve implantation: a 10-year single center experience.


Journal

The Journal of cardiovascular surgery
ISSN: 1827-191X
Titre abrégé: J Cardiovasc Surg (Torino)
Pays: Italy
ID NLM: 0066127

Informations de publication

Date de publication:
Apr 2021
Historique:
pubmed: 5 9 2020
medline: 4 5 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

The aim of this study is to identify clinical, electrocardiographic (ECG) and procedural predictors for permanent pacemaker (PPM) requirement after transaortic valve implantation (TAVI). All consecutive patients with severe symptomatic aortic stenosis (SSAS) undergoing TAVI at our single center were included in the study and prospectively followed. All patients had standard 12-leads ECGs recordings before and after TAVI and continuous ECG monitoring during hospital stay. Primary endpoint was to identify electrocardiographic predictors of PPM implantation after TAVI; secondary endpoint was to ascertain other clinical or procedure-related predictive factors of PPM need. PPM implantation was further arbitrarily divided into early and late one (beyond the 3 Among the 431 patients undergoing TAVI between 2008 and 2018, 77 (18%) needed PPM implantation; 47 (11%) had an early procedure, and 30 (7%) a late implant. Preoperative right bundle branch block (RBBB) implies more than five-fold increase of the risk of PPM implantation (OR 5.19, CI 1.99-13.56, P=0.001), whereas the use of a self-expandable prosthesis is associated with an almost three-fold increase of the risk (OR 2.60, CI 1.28-5.28, P=0.008). In the late PPM implantation subgroup, only the history of syncope retains a significant association with such an increased risk (OR 2.71, CI 1.09-6.75, P=0.032). The need of a PPM in the individual TAVI patient is hardly predictable. However, the finding of pre-existing RBBB, the use of self-expandable prosthesis and history of syncope can individuate patients at increased risk.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study is to identify clinical, electrocardiographic (ECG) and procedural predictors for permanent pacemaker (PPM) requirement after transaortic valve implantation (TAVI).
METHODS METHODS
All consecutive patients with severe symptomatic aortic stenosis (SSAS) undergoing TAVI at our single center were included in the study and prospectively followed. All patients had standard 12-leads ECGs recordings before and after TAVI and continuous ECG monitoring during hospital stay. Primary endpoint was to identify electrocardiographic predictors of PPM implantation after TAVI; secondary endpoint was to ascertain other clinical or procedure-related predictive factors of PPM need. PPM implantation was further arbitrarily divided into early and late one (beyond the 3
RESULTS RESULTS
Among the 431 patients undergoing TAVI between 2008 and 2018, 77 (18%) needed PPM implantation; 47 (11%) had an early procedure, and 30 (7%) a late implant. Preoperative right bundle branch block (RBBB) implies more than five-fold increase of the risk of PPM implantation (OR 5.19, CI 1.99-13.56, P=0.001), whereas the use of a self-expandable prosthesis is associated with an almost three-fold increase of the risk (OR 2.60, CI 1.28-5.28, P=0.008). In the late PPM implantation subgroup, only the history of syncope retains a significant association with such an increased risk (OR 2.71, CI 1.09-6.75, P=0.032).
CONCLUSIONS CONCLUSIONS
The need of a PPM in the individual TAVI patient is hardly predictable. However, the finding of pre-existing RBBB, the use of self-expandable prosthesis and history of syncope can individuate patients at increased risk.

Identifiants

pubmed: 32885926
pii: S0021-9509.20.11342-9
doi: 10.23736/S0021-9509.20.11342-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-174

Auteurs

Daniele Errigo (D)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy - daniele.errigo@gmail.com.

Pier G Golzio (PG)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Fabrizio D'Ascenzo (F)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Enrico Ragaglia (E)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Francesco Bruno (F)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Stefano Salizzoni (S)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Mattia Peyracchia (M)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Davide Castagno (D)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Carlo Budano (C)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Maurizio D'Amico (M)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Simone Frea (S)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Enrico Baldi (E)

Cardiac Intensive Care Unit, Division of Arrhythmia and Electrophysiology and Experimental Cardiology, Department of Medicine Science and Infective Disease, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Carla Giustetto (C)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Gaetano M DE Ferrari (GM)

Division of Cardiology, Department of Internal Medicine, Molinette Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH